Clinical Trial

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blind Phase 3 study to compare the efficacy and safety of Sindilizumab combined with chemotherapy or placebo combined with chemotherapy for neoadjuvant and adjuvant therapy for Resectable Stage II to IIIB (resectable N2 only) non-small cell lung cancer (NSCLC).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-11-02; most recent amendment 2025-06-22.
Status change: Recruiting → Active, Not Recruiting 2025-06-22
Status change: Not Yet Recruiting → Recruiting 2024-03-24
Trial Details
NCT Number NCT05116462
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 506 participants
Start Date 2024-03-15
Primary Completion 2026-09-30 (estimated)
Study Completion 2028-10-14 (estimated)
Updated on ClinicalTrials.gov 2025-06-26